

Masahiro Takeuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8385796/publications.pdf>

Version: 2024-02-01

72
papers

726
citations

516710

16
h-index

610901

24
g-index

73
all docs

73
docs citations

73
times ranked

1354
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. <i>Nature Communications</i> , 2015, 6, 8951.	12.8	59
2	Restrictive usage of monoclonal immunoglobulin λ light chain germline in POEMS syndrome. <i>Blood</i> , 2008, 112, 836-839.	1.4	52
3	Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21455-21467.	4.1	38
4	Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. <i>Blood</i> , 2018, 131, 2173-2176.	1.4	36
5	CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. <i>European Journal of Haematology</i> , 2008, 80, 245-250.	2.2	35
6	Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2013, 97, 520-524.	1.6	33
7	A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS. <i>Nature Immunology</i> , 2021, 22, 893-903.	14.5	33
8	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. <i>Leukemia</i> , 2019, 33, 1723-1735.	7.2	28
9	The Soluble Form of LR11 Protein Is a Regulator of Hypoxia-induced, Urokinase-type Plasminogen Activator Receptor (uPAR)-mediated Adhesion of Immature Hematological Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 11877-11886.	3.4	27
10	Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. <i>Experimental and Molecular Medicine</i> , 2014, 46, e89-e89.	7.7	25
11	Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. <i>Clinica Chimica Acta</i> , 2012, 413, 1542-1548.	1.1	22
12	Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. <i>European Journal of Haematology</i> , 2007, 79, 382-391.	2.2	19
13	Direct activation of STAT5 by ETV6- Δ LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. <i>British Journal of Haematology</i> , 2011, 153, 589-598.	2.5	18
14	Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. <i>Annals of Hematology</i> , 2018, 97, 655-662.	1.8	18
15	Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation. <i>American Journal of Hematology</i> , 2011, 86, 886-888.	4.1	17
16	Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation. <i>Leukemia Research Reports</i> , 2013, 2, 67-69.	0.4	16
17	Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 95-103.	2.5	16
18	Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status. <i>International Journal of Hematology</i> , 2014, 99, 513-518.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 50, 85-94.	0.8	15
20	Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. <i>International Journal of Hematology</i> , 2018, 107, 173-184.	1.6	15
21	Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>PLoS ONE</i> , 2019, 14, e0221941.	2.5	15
22	LR11: a novel biomarker identified in follicular lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 277-280.	2.5	13
23	Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma. <i>Clinica Chimica Acta</i> , 2014, 430, 48-54.	1.1	13
24	Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. <i>International Journal of Hematology</i> , 2012, 95, 204-208.	1.6	11
25	Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. <i>British Journal of Haematology</i> , 2013, 163, 286-289.	2.5	10
26	Safety and Efficacy of Granulocyte Colony-Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 361-363.	2.0	9
27	Clonal immunoglobulin λ light chain gene rearrangements detected by next generation sequencing in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 93, 1161-1168.	4.1	9
28	Acute Myeloid Leukemia Concurrent with Spinal Epidural Extramedullary Myeloid Sarcoma Accompanied by a High CD25 Expression and the FLT3-ITD Mutation. <i>Internal Medicine</i> , 2014, 53, 1159-1164.	0.7	8
29	Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1781-1783.	1.8	8
30	Soluble LR11, a Novel Acute Leukemia Marker, Drastically Induces WT1 mRNA Expression Together with Synergic Activation of Gatas, and the Migration Activity. <i>Blood</i> , 2012, 120, 4795-4795.	1.4	8
31	Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2391-2394.	1.3	7
32	Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. <i>Clinica Chimica Acta</i> , 2016, 463, 47-52.	1.1	7
33	The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet. <i>Internal Medicine</i> , 2017, 56, 353-356.	0.7	7
34	Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). <i>International Journal of Hematology</i> , 2018, 107, 578-585.	1.6	6
35	Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 141-148.	2.1	6
36	Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 330-335.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 86-92.	1.6	5
38	Successful Allogeneic Stem Cell Transplantation for Severe Aplastic Anemia after Treatment of Lymphoproliferative Disorder Caused by Rabbit Antithymocyte Globulin. <i>Internal Medicine</i> , 2015, 54, 3197-3200.	0.7	4
39	Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2982-2985.	1.3	4
40	Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells. <i>Haematologica</i> , 2020, 105, e216-e220.	3.5	4
41	Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis. <i>Transfusion and Apheresis Science</i> , 2016, 54, 276-281.	1.0	3
42	Long-term complete remission by infusion of ex vivo-expanded donor-derived CD4+lymphocytes for treating an early relapse of Hodgkin lymphoma after cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 230-232.	1.3	3
43	Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma. <i>International Journal of Hematology</i> , 2018, 108, 452-455.	1.6	3
44	Myeloid/Lymphoid Neoplasm with <i>PDGFRB</i> Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the <i>CCDC6-PDGFRB</i> Fusion Gene. <i>Internal Medicine</i> , 2019, 58, 3449-3453.	0.7	3
45	The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. <i>Scientific Reports</i> , 2021, 11, 2074.	3.3	3
46	Activation of Rac1 through FARP1 Induces Dexamethasone Resistance in Multiple Myeloma Cells. <i>Blood</i> , 2014, 124, 2248-2248.	1.4	3
47	Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia. <i>Annals of Hematology</i> , 2006, 86, 67-69.	1.8	2
48	Gradually-Deteriorating Liver Function due to Iron Overload Over Four Years after Allogeneic Stem Cell Transplantation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2015, 55, 109-112.	0.8	2
49	The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4414-4414.	1.4	2
50	Serum Soluble LR11 As a Novel Biomarker for B Cell Lymphoma. <i>Blood</i> , 2011, 118, 1581-1581.	1.4	2
51	Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. <i>Experimental Hematology</i> , 2021, 101-102, 34-41.e4.	0.4	1
52	Partial Splenic Embolization For The Treatment Of Steroid-Resistant Chronic Idiopathic Thrombocytopenic Purpura. <i>Blood</i> , 2013, 122, 3543-3543.	1.4	1
53	Diverse Role of DNA Hypermethylation in Reduced Expression of Tumor Suppressor NR4A3 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3640-3640.	1.4	1
54	EFFICACY AND SIGNIFICANCE OF A CONSULTING CLINIC FOR RELATED FAMILY DONORS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AT THE DEPARTMENT OF TRANSFUSION MEDICINE AND CELL THERAPY. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2017, 63, 592-598.	0.2	0

#	ARTICLE	IF	CITATIONS
55	T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1591-1594.	1.3	0
56	Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 221-224.	1.3	0
57	Prognostic Impact of a Novel Biomarker, Serum Soluble LR11 on Acute Leukemia. <i>Blood</i> , 2010, 116, 2717-2717.	1.4	0
58	LR11 Is a Novel Surface Marker for Normal Leukocytes and Leukemia Cells. <i>Blood</i> , 2010, 116, 4834-4834.	1.4	0
59	Direct Activation of STAT5 by TEL-Lyn Fusion Protein Promotes Induction of Myeloproliferative Neoplasms with Myelofibrosis. <i>Blood</i> , 2010, 116, 4114-4114.	1.4	0
60	Outcome After First Relapse In Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 3084-3084.	1.4	0
61	Soluble LR11/SorLA, a Potential Circulating Marker Indicating the G-CSF-Induced Mobilization of Hematopoietic Stem Cells, Is a Modulator of G-CSF-Mediated Migration of HL-60 Cells,. <i>Blood</i> , 2011, 118, 3210-3210.	1.4	0
62	Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis. <i>Journal of Hematopoietic Cell Transplantation</i> , 2012, 1, 15-23.	0.1	0
63	Serum Soluble LR11 Can Predict High FLIPI-2 Score in Follicular Lymphoma.. <i>Blood</i> , 2012, 120, 2673-2673.	1.4	0
64	LR11 Is a Potential Serum and Histological Biomarker for Intravascular Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 5104-5104.	1.4	0
65	LR11 Plays a Critical Role in Leukemogenesis of Acute Myeloid Leukemia by Regulating Adhesion and Homing Ability to Bone Marrow.. <i>Blood</i> , 2012, 120, 2409-2409.	1.4	0
66	Tetraspanin CD9 Inhibits ADAM17-Mediated LR11 Shedding In Leukemia Cells. <i>Blood</i> , 2013, 122, 1035-1035.	1.4	0
67	Impact of Serum Soluble LR11 on Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter Prospective Study. <i>Blood</i> , 2014, 124, 1661-1661.	1.4	0
68	Soluble LR11, GCSF α -induced Migration Regulator from Myeloid Cells, Is Highly Increased in Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 4961-4961.	1.4	0
69	Clonal Immunoglobulin λ Light-Chain Gene Rearrangements Detected By Next Generation Sequencing in POEMS Syndrome. <i>Blood</i> , 2016, 128, 4405-4405.	1.4	0
70	Distinctive Genetic Features of Plasma Cells in POEMS Syndrome. <i>Blood</i> , 2016, 128, 4404-4404.	1.4	0
71	Anagrelide Inhibits Proliferation and Platelet Generation in Immortalized Megakaryocyte Progenitor Cell Lines Established from Human Induced Pluripotent Stem Cells. <i>Blood</i> , 2018, 132, 1789-1789.	1.4	0
72	Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing. <i>Blood</i> , 2019, 134, 1748-1748.	1.4	0